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Abstract
Bronchiectasis is an increasingly common disease with a significant impact on
quality of life and morbidity of affected patients. It is also a very heterogeneous
disease with numerous different underlying etiologies and presentations. Most
treatments for bronchiectasis are based on low-quality evidence; consequently,
no treatments have been approved by the US Food and Drug Administration or
the European Medicines Agency for the treatment of bronchiectasis. The last
several years have seen numerous clinical trials in which the investigational
agent, thought to hold great promise, did not demonstrate a clinically or
statistically significant benefit. This commentary will review the likely reasons
for these disappointing results and a potential approach that may have a
greater likelihood of defining evidence-based treatment for bronchiectasis.
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Bronchiectasis is an increasingly common disease. In the US, 
the condition was being actively treated in an estimated 340,000 
to 522,000 patients in 20131–3. These same data suggested an 
annual increase in prevalence of 8%1. When the authors of this 
commentary were developing an interest in bronchiectasis, it 
was widely considered an orphan disease4. There were no treat-
ments approved by the US Food and Drug Administration (FDA) 
or the European Medicines Agency (EMA), and there was limited 
evidence of interest among pharmaceutical companies in devel-
oping therapies that would change that situation. Then, around 
10 years ago, it appeared that bronchiectasis was an orphan no 
longer. Patient registries dedicated to research were initiated, 
first in the United States and then in Europe and the Asia-Pacific 
region5,6. Perhaps, informed by epidemiologic studies reveal-
ing that the prevalence of bronchiectasis was much greater 
than that of cystic fibrosis (CF) (for which there are numerous 
FDA-approved therapies), pharmaceutical companies started 
showing interest. Ultimately, after initial study, a series of clinical 
trials, including phase III clinical trials, were conducted, and 
there was great hope that the results would usher in a new era of 
evidence-based high-quality care7–10. Unfortunately, these studies 
either failed to meet their primary endpoint or demonstrated 
inconsistent benefit. Inhaled mannitol failed10. Inhaled aztreonam 
failed7. Inhaled colistin failed11. Inhaled dry powder ciprofloxacin 
failed8,9,12. Consequently, in 2018, there were still no therapies 
approved for bronchiectasis by the FDA or EMA. This commen-
tary will explore potential explanations for these failures and 
discuss a recommended path forward.
Are we studying some drugs in the wrong disease?
Most therapies that have been studied in patients with bron-
chiectasis were initially developed and used to treat CF13. At some 
level, this makes sense; the two conditions share the commonal-
ity of impaired airway local host defenses and resulting chronic 
airway infection. However, bronchiectasis is not CF.
DNase (dornase alpha) is a mucolytic, as DNA released extra-
cellularly from polymorphonuclear leukocytes imparts much 
of the viscosity of CF sputum14–16. DNase slows the loss of 
pulmonary function in CF and is a mainstay of treatment. 
However, in bronchiectasis, DNase resulted in increased risk of 
pulmonary exacerbations compared with placebo and no benefit 
in any other parameters16.
Hypertonic saline nebulization, commonly used as an adjunct for 
airway clearance therapy in CF, acts as an osmotic agent, drawing 
water into the airways. However, in a 12-month randomized 
controlled trial, 6% saline was no better than isotonic saline 
with respect to effect on quality of life (QoL) and pulmonary 
function17. Mannitol, in addition to functioning as an osmotic 
agent, enhances ciliary beat frequency, theoretically resulting in 
easier sputum clearance10,18. Because it persists in the airway for 
longer than hypertonic saline, it was hoped that it would be more 
effective in improving mucociliary and cough clearance. Indeed, it 
resulted in improved pulmonary function in patients with CF and 
was approved for use in the UK and Australia. In 2014, a phase 
III trial of inhaled mannitol in bronchiectasis was reported10. 
There were no significant improvements in the primary end-
point: exacerbation rate with inhaled mannitol; consequently, it 
is not approved anywhere for use in bronchiectasis. Statistically 
significant improvements were seen in time to first exacerbation 
and St George’s Respiratory Questionnaire (SGRQ), although 
the mean improvement in SGRQ was not greater than the 
minimally important difference10.
The underlying defect in CF is abnormally viscous and 
tenacious mucus, which impairs cough and ciliary clearance19. 
The fundamental epithelial and ciliary defects are understood, and 
drugs such as DNase and mannitol have been specifically formu-
lated on the basis of this knowledge. In contrast, there has been 
minimal research into cilia or epithelial function in bron-
chiectasis, and mucus characteristics are poorly understood20. 
However, in most patients with bronchiectasis, the mucus is 
normal, and most patients seem to have less difficulty clearing 
it unless they develop advanced disease that impairs cough 
efficacy. Therefore, it is not surprising (in retrospect) that thera-
pies aimed at reducing mucus viscosity and increasing mucus water 
content might not be useful in many patients with bronchiectasis 
despite the demonstrated benefit in CF. Indeed, one study 
demonstrated that, in contrast to CF, DNase worsened mucus 
transportability in bronchiectasis and therefore may exacerbate 
airway obstruction21. Ongoing or planned studies of agents tar-
geting mucociliary clearance include studies of N-acetylcysteine 
and an epithelial sodium channel (ENaC) inhibitor, VX-37120.
Are we studying the right drugs in the right patients 
but giving the drugs the wrong way?
Worldwide, inhaled antibiotics are frequently used “off-label” in 
bronchiectasis. These include tobramycin, colistin, gentamicin, 
aztreonam, and vancomycin. Expert opinion, early-phase stud-
ies, and even some phase III trials suggest that these agents 
result in significant improvement in QoL and reduce frequency 
of exacerbations in some patients with bronchiectasis22,23. In 
contrast to the practice in Europe, where inhaled antibiotics are 
given on a continuous schedule, in the US, most patients with 
bronchiectasis are given inhaled antibiotics on a 28-days-on/28-
days-off schedule23. This schedule originated with the phase 
III study of inhaled tobramycin for CF, published in 199924. 
The reported rationale for this schedule was that the off periods 
would “allow susceptible pathogens to repopulate the airways 
in patients with cystic fibrosis”, thereby limiting the develop-
ment of resistance6. However, it is not clear that this rationale 
makes sense for repeated cycles, and a recent systematic review 
in bronchiectasis confirms that the hypothesis that this approach 
would limit resistance development has never been tested25. In 
addition to the continuous use of a single inhaled antibiotic, 
there is evidence in CF suggesting improved outcomes with the 
use of continuous alternating inhaled antibiotics, specifically 
patients did better with inhaled tobramycin alternating with inhaled 
aztreonam (each for 28 days), compared with inhaled tobramycin 
for 28 days alternating with 28 days of placebo26.
Another rationale for the 28-day on/off schedule is that the 1999 
CF tobramycin study demonstrated that the achievable increase 
in FEV1 (forced expiratory volume in 1 second) from inhaled 
antibiotics occurred at 28 days and further increases were not 
seen with a longer course24. However, there are reasons to 
question the wisdom of this practice. As mentioned above, FEV1 
Page 3 of 7
F1000Research 2019, 8(F1000 Faculty Rev):293 Last updated: 15 MAR 2019
improvement is not an appropriate outcome for bronchiecta-
sis, as FEV1 is generally impacted to a lesser extent compared 
with CF by exacerbations and responds minimally to antibiotic 
treatment for bronchiectasis11. A potential indication that the 
28-day cycle is not the optimum schedule for bronchiectasis 
comes from the recently reported RESPIRE 1 trial, in which a 
14-day on/off cycle of inhaled ciprofloxacin dry powder 
improved time to first exacerbation and exacerbation frequency 
compared with placebo but a 28-day on/off cycle did not8,9. 
This observation is certainly not definitive, as the identically 
structured RESPIRE II trial found no statistically significant 
improvements in either outcome in either the 14- or 28-day 
groups, although the trends to improvement were greater in the 
28-day on/off patients8,9. However, it is not unusual for patients 
on the 28-day on/off regimen to report increasing cough and 
sputum production near the end of their 28-day off cycle and 
bacterial density certainly increases by the end of the off cycle7.
Are we studying the right drugs in the right patients 
but using the wrong outcomes?
Most of the large clinical trials in bronchiectasis have used 
frequency of exacerbation or time to exacerbation as the 
primary outcome8,9,11. There is no doubt that exacerbations are an 
important cause of morbidity and, to a lesser extent, mortality in 
patients with bronchiectasis27,28. But for many patients, the daily 
burden of cough and sputum is perceived as an equal or greater 
concern29. Furthermore, in most patients, exacerbations are 
comparatively uncommon events, occurring once or twice a 
year6,30. This creates several problems. First, since there needs to 
be a high-enough baseline exacerbation rate to allow detection 
of a drug effect, most trials enroll patients with only two or more 
exacerbations in the prior year. So we have been studying a non- 
representative, relatively low-prevalence patient subgroup (albeit 
one with a markedly worse prognosis)31. Furthermore, we have 
frequently used a primary endpoint that may have less significance 
to the patient than to us investigators. The analysis of exacerba-
tions is also complicated by the multiple different methods of 
analysis, including the time to first exacerbation, which is a rela-
tively “clean” endpoint but which ignores all events following 
the first exacerbation, therefore potentially reducing the com-
plex impact of bronchiectasis on a patient life over decades to a 
single point in time. Exacerbation frequency is more holistic 
but is complicated by the challenge of separating whether 
multiple antibiotic courses within a short time represent distinct 
exacerbations or a single worsening of symptoms. Exacerba-
tions are also inter-dependent events, as patients are much 
more likely to have another exacerbation soon after they have 
the first28. Commonly used methods of analysis for exacerbations 
such as negative binomial models fail to account for this.
A common joke among bronchiectasis specialists is that the 
best way to prevent exacerbations among our patients is to 
consider enrolling them in a clinical trial. Most studies have 
shown lower-than-expected exacerbation rates in the placebo 
group, limiting the potential for positive results8,9. Although 
the closer medical attention paid to clinical trial participants 
might be partly responsible, regression to the mean is likely a 
major factor. Consider a patient who for many years has had 
zero or one exacerbation a year but who one year has an addi-
tional exacerbation after being exposed to her sick grandchild. 
She qualifies for the trial by virtue of her two exacerbations, but 
there is no reason to expect that she and patients like her are at 
high ongoing risk of exacerbation during the trial.
An ongoing phase III clinical trial of an agent that prevents 
release of neutrophil proteases is also using time to exacerbation 
as the primary outcome32. Proteases contribute to progressive 
airway damage and increase mucus secretion in patients with 
bronchiectasis33, so one could theorize that such a drug could be 
beneficial in decreasing cough, improving QoL, and prevent-
ing progression of disease without decreasing the frequency of 
exacerbations, which of course are usually caused by infectious 
agents. However, the rate of lung function loss in bronchiectasis 
is slow; any study that had lung function as a primary end-
point would likely need to continue for years to have a 
chance of showing benefit.
The issues noted above make it difficult to demonstrate improved 
exacerbation rates or stability of lung function in bronchiecta-
sis clinical trials. Yet there are not any clearly better options 
for primary endpoints. Sputum volume would seem to have face 
validity but for several reasons is not optimum. Some patients 
with bronchiectasis hesitate to expectorate their sputum. Some 
believe a higher volume of sputum production represents clinical 
improvement as the sputum is easier to bring up. Others would 
be thrilled to produce less sputum, whereas some patients are 
worried when they produce less sputum believing that a lower 
quantity of mucus reflects increasing difficulty in sputum clear-
ance and greater sputum retention. Given the heterogeneity 
of bronchiectasis, perhaps each of these perceptions is “correct” in 
some patients34.
QoL, measured with a bronchiectasis-specific instrument, was 
used as the primary endpoint in the phase III inhaled aztre-
onam trials which demonstrated no improvement in QoL in 
AIRBX1 and a small statistically significant improvement which 
did not exceed the minimum clinically important difference in 
AIRBX27. The failure may have been partly related to an increased 
rate of adverse events due to the therapy.
The three trials35–37 demonstrating improved exacerbation rates 
resulting from chronic low-dose macrolide therapy demon-
strated limited and inconsistent benefit with respect to QoL, 
suggesting an important disconnect between exacerbations and 
symptom improvements with therapy. The recent RESPIRE 
trials8,9 used two QoL tools: the Quality of Life-Bronchiectasis 
respiratory symptom score (QoL-B) and the SGRQ. These trials 
again demonstrated this disconnect but also showed conflict-
ing results with the two tools, suggesting that they may measure 
subtly different aspects of the disease. Some regulatory agen-
cies have been unenthusiastic about accepting QoL as a primary 
endpoint for bronchiectasis trials. Although QoL and symptoms 
are an enormously important outcome for patients with bron-
chiectasis and in an ideal world would be the primary endpoint 
in trials, there is insufficient confidence in the existing tools to 
recommend using one as the primary endpoint in a future trial. 
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Other potentially useful QoL tools for bronchiectasis trials 
include the Leicester Cough Questionnaire, which has been used 
in positive trials of cough-related illness38, and the Bronchiectasis 
Health Questionnaire, with which there is less clinical experi-
ence than the QoL-B but which has the potential advantages 
of being briefer and yielding a single score39. Finally, meas-
urement of cough frequency is a potential objective outcome 
that may correlate well with QoL in patients with bronchiectasis40.
Are we studying the right drugs but not identifying 
the right subpopulations of patients with 
bronchiectasis who would benefit from them?
Bronchiectasis is an extremely heterogeneous disease33. Patients 
differ greatly in terms of underlying etiology, severity of 
disease, frequency of exacerbations, and prognosis41. Under-
lying the relatively subtle clinical differences evident in daily 
practice are multiple complex endotypes (biological processes 
which link to clinical manifestations or treatment response)20,33. 
The era of personalized medicine in CF and asthma has led 
to the use of therapies targeted on the basis of genotype and 
biomarkers. Bronchiectasis is substantially more heterogene-
ous than these two conditions, but for the most part, other than 
requiring evidence of exacerbations during the prior year and 
chronic sputum production (and an appropriate target organism 
for inhaled antibiotic trials), most trials have not distinguished 
between different phenotypes of patients.
Two phase II studies of oral neutrophil elastase inhibitors (BAY 
85-8501 and AZD9668) have been conducted during the last 
5 years without clear evidence of beneficial effects but did not 
include patients on the basis of elevated levels of neutrophil 
elastase or other neutrophil biomarkers42,43. Twenty to thirty 
percent of patients with bronchiectasis appear to have predomi-
nantly eosinophilic- or non-neutrophil-dominant inflammation44. 
The aim of inhaled antibiotics is to reduce bacterial load, 
and high bacterial loads are associated with airway inflam-
mation and future exacerbation risk45. Yet inhaled antibiotic 
studies enroll patients with positive sputum cultures which may 
include levels of bacteria not associated with exacerbation 
risk and not likely to respond to inhaled antibiotics8,9. Inhaled 
corticosteroids are widely used in clinical practice but as yet have 
not been targeted toward eosinophilic inflammation where 
response has been demonstrated in other diseases46. Mucoactive 
drugs are tested in populations of patients with widely hetero-
geneous sputum characteristics without establishing whether 
sputum DNA is elevated (in the case of DNase) or mucus 
dehydration is present (in the case of mannitol). Simple and 
easy-to-identify biomarkers could help to identify patients 
who would be more likely to benefit from specific therapies. It 
remains to be seen whether specific bronchiectasis etiologies 
can help predict the presence of these biomarkers, although at 
this point there is no such evidence. Distinct from the underlying 
bronchiectasis etiology, the different patient characteristics and 
biomarkers which link to treatment responses can be called 
“treatable traits” and this approach has great potential to cut 
through the complexity of bronchiectasis to perform more targeted 
and more rational clinical trials47.
Summary
Bronchiectasis is an extremely heterogeneous condition that 
exacts a tremendous toll on QoL of many afflicted patients. The 
initial optimism about the increasing attention being paid to 
bronchiectasis in the last decade has waned somewhat with each 
successive trial that did not demonstrate improvement in the 
primary endpoint. There appear to be multiple reasons for 
these results, but they include application of principles 
relevant to CF without adequate consideration of the differences 
between the two diseases. Another has been incomplete char-
acterization of the phenotypic, genetic, and endotypic varia-
tions in patients with bronchiectasis, such that potential thera-
pies are applied to “all comers”, even though many patients 
might not have characteristics that would predict therapeutic 
success. Furthermore, determining the appropriate primary 
endpoint is difficult in this disease as different endpoints are 
relevant for different manifestations of the disease. We propose 
that targeting the underlying determinants of specific character-
istics of patients with bronchiectasis will be more likely to yield 
therapeutic advances that improve QoL and outcomes.
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